{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:39:35Z","timestamp":1753439975051,"version":"3.32.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Saudi Dental Journal"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.sdentj.2022.06.004","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:57:58Z","timestamp":1655773078000},"page":"479-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center"],"prefix":"10.1007","volume":"34","author":[{"given":"Saad","family":"Hajeri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasir","family":"Alturkistany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.sdentj.2022.06.004_b0005","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s11695-014-1542-1","article-title":"The hundred most cited articles in bariatric surgery","volume":"25","author":"Ahmad","year":"2015","journal-title":"Obes. Surg."},{"key":"10.1016\/j.sdentj.2022.06.004_b0010","first-page":"29","article-title":"Prevalence of jaw osteonecrosis among patients receiving bisphosphonates in Riyadh","volume":"2","author":"Alzoman","year":"2011","journal-title":"King Saud Univ. J. Dental Sci."},{"key":"10.1016\/j.sdentj.2022.06.004_b0015","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.sdentj.2022.06.004_b0020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s11914-018-0474-4","article-title":"Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw","volume":"16","author":"Chang","year":"2018","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.sdentj.2022.06.004_b0025","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4103\/0973-1482.126471","article-title":"Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan","volume":"9","author":"Chiang","year":"2013","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.sdentj.2022.06.004_b0030","doi-asserted-by":"crossref","first-page":"1655 e1","DOI":"10.1016\/j.joms.2019.04.015","article-title":"Bibliometric Analysis of Medication-Related Osteonecrosis of the Jaw: High Citation Rates but Low Evidence","volume":"77","author":"Diniz-Freitas","year":"2019","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.06.004_b0035","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.coms.2015.06.003","article-title":"The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors","volume":"27","author":"Dodson","year":"2015","journal-title":"Oral Maxillofac. Surg. Clin. North Am."},{"key":"10.1016\/j.sdentj.2022.06.004_b0040","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2008.11.029","article-title":"Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies","volume":"112","author":"Fehm","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.sdentj.2022.06.004_b0045","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2016.1177021","article-title":"Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology","volume":"15","author":"Fusco","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.sdentj.2022.06.004_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.sdentj.2022.06.004_b0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.oooo.2018.11.012","article-title":"Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review","volume":"127","author":"King","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.sdentj.2022.06.004_b0060","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients","volume":"26","author":"Kyrgidis","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.sdentj.2022.06.004_b0065","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.joms.2008.01.026","article-title":"Inhibition of oral mucosal cell wound healing by bisphosphonates","volume":"66","author":"Landesberg","year":"2008","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.06.004_b0070","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.06.004_b0075","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10549-009-0432-z","article-title":"Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis","volume":"116","author":"Mauri","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.sdentj.2022.06.004_b0080","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review","volume":"27","author":"Nicolatou-Galitis","year":"2019","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.sdentj.2022.06.004_b0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials","volume":"19","author":"Qi","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.sdentj.2022.06.004_b0090","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.sdentj.2022.06.004_b0095","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"RE Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.06.004_b0100","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","volume":"41","author":"Reid","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.sdentj.2022.06.004_b0105","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.sdentj.2022.06.004_b0110","article-title":"American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.06.004_b0115","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20132009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.06.004_b0120","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.06.004_b0125","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.sdentj.2022.06.004_b0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bjoms.2019.09.023","article-title":"Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF-alpha) inhibitors: a systematic review","volume":"58","author":"Sacco","year":"2020","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.06.004_b0135","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.sdentj.2022.06.004_b0140","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.sdentj.2022.06.004_b0145","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1007\/s00520-013-1934-0","article-title":"Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors","volume":"21","author":"Van den Wyngaert","year":"2013","journal-title":"Support. Care Cancer"}],"container-title":["The Saudi Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S101390522200075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S101390522200075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:28:52Z","timestamp":1736184532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S101390522200075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S101390522200075X"],"URL":"https:\/\/doi.org\/10.1016\/j.sdentj.2022.06.004","relation":{},"ISSN":["1013-9052"],"issn-type":[{"type":"print","value":"1013-9052"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center","name":"articletitle","label":"Article Title"},{"value":"The Saudi Dental Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sdentj.2022.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}